Home › Colorectal Cancer › NCT07033026

An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

A Phase 2, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants With Colorectal Cancer Who Have Cancer Cachexia

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Documented active diagnosis of colorectal cancer.
2. Cachexia defined by Fearon criteria of weight loss.
3. Signed informed consent.

Exclusion Criteria:

1. Current active reversible causes of decreased food intake.
2. Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization.
3. Have cachexia caused by other reasons.

About the study

A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.

What is being tested

• NGM120 Q4W (drug)
• NGM120 Q8W (drug)
• Placebo given (drug)

Sponsor: NGM Biopharmaceuticals, Inc · Participants: 136 · Started: Jun 25, 2025

Contact the study team

• NGM Study Director · Phone: 650-727-8800

Official record on ClinicalTrials.gov — NCT07033026

Locations in the U.S.

Conditions

• Colorectal Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.